17.11.2014 • NewsaccidentDuPontTexas

Accident at DuPont Texas Plant Kills Four

Four workers employed by DuPont were killed and one was injured in the early morning hours of Nov.15 during a leak methyl mercaptan at a production facility of the US chemical giant at La Porte, Texas, east of Houston.

The plant uses the chemical as a starting material for crop protection products. DuPont said the cause of the accident had not been determined. The U.S. Chemical Safety Board is investigating

Facility management said the employees had responded to the leak in a valve.

Some 320 of the employees of the plant work for DuPont. Four other companies are also tenants at the complex.

The five workers were the only ones in the unit at the time of the incident and were exposed to the chemical, DuPont said. Four died at the plant, and one was still hospitalized on Nov. 17.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.